What’s the current market cap for Prestige Consumer Healthcare stock?

Prestige Consumer Healthcare (PBH) has a market cap of $2.3B as of May 29, 2026.

What is the P/E ratio for Prestige Consumer Healthcare stock?

The price to earnings (P/E) ratio for Prestige Consumer Healthcare (PBH) stock is 12.4 as of May 29, 2026.

Does Prestige Consumer Healthcare stock pay dividends?

No, Prestige Consumer Healthcare (PBH) stock does not pay dividends to its shareholders as of May 29, 2026.

When is the next Prestige Consumer Healthcare dividend payment date?

Prestige Consumer Healthcare (PBH) stock does not pay dividends to its shareholders.

What is the beta indicator for Prestige Consumer Healthcare?

Prestige Consumer Healthcare (PBH) has a beta rating of 0.4. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy Prestige Consumer Healthcare stock | $PBH Share Price

About Prestige Consumer Healthcare

Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.

Ticker

$PBH

Sector

Health

Primary listing

NYSE

Employees

890

Headquarters

Tarrytown, United States

Website

www.prestigebrands.com

PBH Metrics

BasicAdvanced

$2.3bn

12.40

$3.91

0.40

-

What the Analysts think about PBH

Analyst ratings (Buy, Hold, Sell) for Prestige Consumer Healthcare stock.

Bulls say / Bears say

The acquisition of the Breathe Right brand for $1.045 billion expands Prestige’s portfolio into the high-growth sleep wellness category, adding approximately $200 million in revenue and $95 million in core profit, and is expected to be accretive to core profit (Reuters).

The acquisition of Pillar5 Pharma secures the supply chain for the Clear Eyes portfolio, improving manufacturing capacity and mitigating previous supply-driven revenue headwinds in eye care (Reuters).

Strong international OTC segment growth in Q1 FY2026 partially offset North American headwinds, demonstrating the benefits of geographic diversification in revenue streams (Reuters).

Revenue and EPS missed consensus in Q1 FY2026 due to Clear Eyes supply constraints, indicating persistent operational headwinds (Reuters).

Prestige lowered its fiscal 2026 revenue outlook to $1.10–$1.115 billion, reflecting downward revisions amid supply challenges and tepid demand (Reuters).

Q4 FY2026 revenue of $281.6 million missed the $293.7 million IBES consensus, underscoring continued top-line weakness across core categories (Reuters).

Data summarised monthly by Lightyear AI. Last updated on 20 May 2026.

PBH Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

PBH Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

PBH News

AllArticlesVideos

Protect Your Investment: Contact Levi & Korsinsky About the Prestige Consumer Healthcare Inc. (PBH) Investigation

Newsfile Corp·5 days ago

Securities Fraud Investigation Into Prestige Consumer Healthcare (PBH) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

Business Wire·7 days ago

Prestige Consumer Healthcare (PBH) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

Business Wire·7 days ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.